This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Jazz Pharmaceuticals plc

Drug Names(s): C-10323, deuterium-modified sodium oxybate, D-SXB

Description: C-10323 is a deuterium-modified sodium oxybate developed through Concert's DCE Platform (Deuterated Chemical Entity). Sodium oxybate is the active ingredient in Xyrem.

Concert's DCE Platform involves selective deuterium modification to existing compounds which usually have less than ideal ADME profiles. This platform has the potential to improve ADME without altering desirable pharmacological properties.

Deal Structure: Concert and Jazz
In February 2013, Concert and Jazz entered into an exclusive license agreement that provides Jazz worldwide rights to develop and commercialize Concert's deuterium-modified sodium oxybate (D-SXB) compounds, including C-10323. Under the agreement, Jazz will have worldwide commercial rights to C-10323, as well as principal responsibility for ongoing development activities. Concert will receive an upfront payment and is eligible to receive additional milestone payments as well as tiered royalties based on potential worldwide sales of any D-SXB products.

Partners: Concert Pharmaceuticals, Inc.

JZP-386 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug